Our passion is improving patient outcomes. Patients are the centre of everything we do
Leadership
-
-
Clifford Bleustein, MD, MBA
President and CEO
Dr. Clifford Bleustein is the Global President and CEO of AposHealth. Prior to AposHealth, Dr. Bleustein was President and CEO of Computer Task Group (NASDAQ: CTG), where he managed >3400 people globally and >$340M in revenue across healthcare, technology services, energy, and financial services with operations in North America, Western Europe, and India. Dr. Bleustein went to CTG from Dell, where he had several roles, rising to become the Chief Medical Officer and Global Healthcare Solutions Leader with P&L responsibility for Healthcare & Life Sciences Solutions globally. Dr. Bleustein also had a successful period as a consultant at PwC, rising to Director with a diverse experience of projects including interim executive director of outpatient services, business strategy, international “biocluster” development, mergers & acquisitions, healthcare operations, physician alignment, governance, and resource optimization. He also has on-the-ground experience in the UK, Ireland, India, South Africa, and China, with assessments in the Middle East / Asia.Dr.Bleustein graduated from the Medical College of Wisconsin and completed his internship at the New York Hospital Medical Center of Queens. He later completed his residency in urology at Montefiore Medical Center. He went on to private practice Urology and became a board-certified Urologist. He has an extensive roster of peer-reviewed published research and 2 patents. Dr. Bleustein earned a bachelor’s degree in science from the University of Wisconsin, Madison. He also received an executive master’s degree in business administration from NYU Stern School of Business, where he now teaches Healthcare Economics as an Adjunct Professor.
-
-
Nina Cha, PT, DPT
VP, Clinical Services
Nina joined AposHealth in 2014. She holds a Doctorate in Physical Therapy and is an experienced Clinical Specialist in mobility, gait analysis, biomechanics, and neuroscience. Nina is known for her innovative approach and dedication to improving patient care. She has successfully advanced clinical operations by collaborating with research and business development teams, demonstrating her ability to integrate multidisciplinary efforts for optimal outcomes. Nina has developed and led priority training projects, including a comprehensive virtual training program that spans multiple departments. Her leadership was pivotal in overhauling the clinical training program to enhance telehealth capabilities, focusing on reducing delivery and contact time while optimizing clinical outcomes and operational costs. Her strategic thinking and commitment to excellence have driven forward-thinking clinical strategies and innovations, significantly contributing to the growth and success of the organization. -
-
Jed Dow
VP, Client Relationships
Prior to joining AposHealth in 2019, Jed was the leader of voluntary benefits, leaves, and wellness at Deloitte, where he was responsible for leading a growing portfolio of employee benefit programs. His responsibilities included strategy, implementation, regulatory compliance, and ongoing management of 25 benefits and programs offered to all US employees through collaboration with internal and external stakeholders.Throughout his 25-year career in benefits and wellness, Jed has held multiple positions with growing responsibilities within Deloitte and Johnson & Johnson Health Care Systems, Inc.
-
-
Elizabeth Fitzgerald
VP, Chief Compliance Officer
Elizabeth Fitzgerald leads the compliance program at AposHealth, bringing over 17 years of diverse experience across both payor and provider aspects of healthcare operations, complemented by five years as a regulator. Her comprehensive and strategic approach ensures operational efficiency, compliance, and scalability.Elizabeth earned her bachelor’s degree from Randolph-Macon Woman’s College (now Randolph College) and her Juris Doctor from Gonzaga University School of Law.
-
-
Veronica Hyatt
VP, Market Leader
Veronica recently joined AposHealth after successfully leading the Client Success function within a mission-driven healthcare services company.Veronica’s career experiences include roles within growth teams across retail, hospitality, wellness, healthcare, and employer benefit spaces. This broad set of experiences gives her a unique perspective to help solve challenges.
She received her undergraduate and graduate degrees in marketing from St. Joseph’s University.
-
-
Fred Lewis
SVP, Chief Operations Officer
Fred has a proven track record of working with healthcare customers to drive value from their investments and driving transformational change. His success over the past 25 years is driven by his dedication to turning vision into reality. He has extensive experience with business development, financial management, budgeting, and organizational change management. Prior to joining AposHealth Fred worked in both Fortune 500 companies and start-ups. In his last position at Nordic Global Consulting, a large healthcare consulting firm, he delivered quality services for healthcare clients around the world. Fred is passionate about transforming healthcare and creating positive experiences for clients and patients. -
-
Omer Ostro, M.Sc., CPA
SVP, Chief Financial Officer
Mr. Ostro has over 15 years of progressive experience in audit and financial management of private and public companies and a proven record in providing high-quality financial management services to companies in various business cycles and sectors.
Previously, Mr. Ostro managed the valuation team of emerging market structured credit desk at Barclays Capital in London, UK, specializing in valuation and risk management of complex derivatives and structured financial products. Prior to that, he served as a Senior Associate in the audit division of PwC, Israel.
Mr. Ostro is a qualified certified public accountant in Israel and holds an MSc in Finance and Economics (with merit) from London School of Economics and a BSc in Economics and Accounting (with magna cum laude) from Tel-Aviv University. -
-
Ganit Segal, MPE, MBA
GM, EVP, Chief Scientific & Innovation Officer
Ganit joined AposHealth in 2006. She holds a master’s degree in life science, with a specialization in biomechanics and has more than 15 years’ experience in medical research including various clinical trial methodologies, scientific publications with over 35 publications in peer-review journals and substantial experience in scientific reviews including global clinical trends and guidelines, comparative analysis and more.
Since 2017, Ganit began laying the company’s foundations to collect and analyze big data in order to support post-marketing clinical activity and ongoing account management and improve patient care.
Board Of Directors
-
-
Clifford Bleustein, MD, MBA
Director, President and CEO
Dr. Clifford Bleustein is the Global President and CEO of AposHealth. Prior to AposHealth, Dr. Bleustein was President and CEO of Computer Task Group (NASDAQ: CTG), where he managed >3400 people globally and >$340M in revenue across healthcare, technology services, energy, and financial services with operations in North America, Western Europe, and India. Dr. Bleustein went to CTG from Dell, where he had several roles, rising to become the Chief Medical Officer and Global Healthcare Solutions Leader with P&L responsibility for Healthcare & Life Sciences Solutions globally. Dr. Bleustein also had a successful period as a consultant at PwC, rising to Director with a diverse experience of projects including interim executive director of outpatient services, business strategy, international “biocluster” development, mergers & acquisitions, healthcare operations, physician alignment, governance, and resource optimization. He also has on-the-ground experience in the UK, Ireland, India, South Africa, and China, with assessments in the Middle East / Asia.Dr.Bleustein graduated from the Medical College of Wisconsin and completed his internship at the New York Hospital Medical Center of Queens. He later completed his residency in urology at Montefiore Medical Center. He went on to private practice Urology and became a board-certified Urologist. He has an extensive roster of peer-reviewed published research and 2 patents. Dr. Bleustein earned a bachelor’s degree in science from the University of Wisconsin, Madison. He also received an executive master’s degree in business administration from NYU Stern School of Business, where he now teaches Healthcare Economics as an Adjunct Professor.
-
-
Joe Mark
Chairman of the board
Joe is Chairman of AposHealth and an investor in healthcare. Over the last 16 years he led investments and held director/ ceo/coo positions in the payor, provider and drug distribution sectors. In the aggregate over $2 billion of incremental exit value was realized on these investments. Previously he was a venture capitalist and an investment banker. He is a graduate of Columbia University and the Wharton Graduate School of Business. -
-
Zeev Zehavi
Director
Since joining Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 1999 as Vice President Venture Investments, Zeev has held multiple positions within the organization. From 2007-2015, Zeev served as the JJDC European representative out of Belgium, covering investments across Europe and Israel for all Johnson & Johnson sectors including Pharmaceuticals, Medical Devices and Consumer.Working closely with Med Tech and Janssen R&D leadership, Zeev has built an innovative portfolio that has resulted in numerous onboardings creating growth engines for J&J and successful exits delivering strong returns for the JJDC and the sector portfolios.
Notable transactions include: Genmab (Darzalex), OrthoTaxy (Velys), Mazor, OrthoSpin, Movetis and FutuRX, an Israeli incubator for early stage Biotech opportunities.
Prior to joining JJDC, Zeev spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years, leading private equity investments in companies within areas of Generic R&D, Drug delivery, Chiral chemistry, and a large Public Commercial US entity.
Zeev has retired from JJDC in December of 2022 and serves as a consultant to Alive Israel HealTech Fund and as Independent Industry expert board member in several companies in the field of Life Sciences. Zeev holds a Bachelor of Science degree from the Hebrew University of Jerusalem and a Master of Business Administration degree in Marketing and Finance from Tel Aviv University.
Advisory Board
-
-
Chuck Bogosta
Chuck Bogosta is a seasoned healthcare executive with over 26 years at UPMC, a $31B academic medical center and integrated delivery and finance system (IDFS). He held multiple leadership roles, including Executive Vice President of UPMC, President of UPMC Hillman Cancer Center, UPMC International, and Strategic Business Initiatives (now UPMC Enterprises). Bogosta played a pivotal role in founding and scaling these business units, pioneering innovative healthcare delivery models.
As President of UPMC Hillman Cancer Center, he led the creation of the world’s largest distributed cancer network, growing it to 75 sites with $1.5B in revenue. At UPMC International, he spearheaded the development of owned and operated hospitals and clinics across 10 countries. With Strategic Business Initiatives, he built UPMC’s private equity-style investment arm, launching multiple commercial ventures in digital innovation and biotech.
In addition to his UPMC tenure, Bogosta has held executive roles in healthcare startups and served as CFO for the University of Pittsburgh Cancer Institute. He currently provides consulting services through Bogosta Enterprises LLC and serves on several Boards of Directors.
Bogosta earned a B.A. in business economics from SUNY, an M.A. in educational administration from Bowling Green State University, and an honorary doctorate from SUNY. In 2022, he received the NCHL International Healthcare Leadership Award for his contributions to global healthcare.
-
-
Gus P. Georgiadis
Mr. Gus P. Georgiadis has nearly forty years of executive-level healthcare experience in both health insurance and employee benefits services. His expertise encompasses the development of go-to-market strategies, as well as strategic product positioning and product/service rollout at pharmaceutical, medical device, and digital healthcare companies.
Mr. Georgiadis currently serves as the Area Chairman of the Gallagher Benefit Services operations in Pittsburgh, Pennsylvania and upstate New York. He founded Triad USA, Inc. in 1998 and served as President until 2012, when he merged the company with Gallagher Benefit Services. Before establishing Triad, Mr. Georgiadis was Executive Vice President for Highmark Blue Cross Blue Shield, one of the largest health insurers in the United States. His experience also includes the creation of multiple businesses and initiatives that today serve as national models for healthcare, including the Gateway Health Plan and the Children’s Health Insurance Program.
Mr. Georgiadis earned a political science and business degree at Westminster College and an executive leadership degree at Duke University’s Fuqua School of Business.
-
-
David Nash, MD, MBA
David B. Nash, MD, MBA, is the Founding Dean Emeritus — and remains on the full-time faculty as the Dr. Raymond C. and Doris N. Grandon Professor of Health Policy — at Thomas Jefferson University’s College of Population Health (JCPH). Dr. Nash has been a hospital trustee for over 20 years and has recently completed nearly a decade as a member of the Board of Directors for Humana, Inc., one of the nation’s largest publicly traded healthcare companies.
In 2014 he joined the board of InfoMC, a leading information technology company in suburban Philadelphia. He is on the Healthcare Advisory Board for Arsenal Capital Partners in NYC and joined the board of Tract Manager, a portfolio company of Arsenal. In late 2018 he joined the board of ANI Pharmaceuticals, a publicly-traded generic drug manufacturer, headquartered in Baudette, MN.
Finally, he is a board member of FOX Rehab, a portfolio company of Blue Wolf Capital. A board-certified internist, Dr. Nash is internationally recognized for his work and has repeatedly been named to Modern Healthcare’s list of Most Powerful Persons in Healthcare.
-
-
Timothy E. Nolan
Tim is Founder & CEO of TEN Healthcare Strategies, LLC. a company specializing in the provision of strategic and tactical business development services in the healthcare space. With over 35 years’ experience, Tim was most recently the EVP of EmblemHealth, an $8 billion not-for-profit health plan payer and provider in the New York metro area. In addition, Tim served as the president and COO of Independent Living Systems, LLC., contributing to its growth as a nationally recognized leader in long-term managed care. Other executive roles have included positions with Meridian Health Systems, now Hackensack Meridian Health, and Coventry Healthcare and USHealthcare. where he played fundamental roles in the acquisition and integration of those organizations by Aetna. Tim currently sits on the OneHome and New York University Wagner School of Health advisory boards.
The members or their institutions of our Advisory Board are compensated for the time they spend working with Apos® to better our products and services.
Medical Advisory
-
-
Joel Block, MD
Joel A Block MD is the Willard L. Wood, MD, Professor of Rheumatology, professor of Medicine, and Chief of the Division of Rheumatology at Rush University Medical Center in Chicago. His early research focused on cartilage biology and chondrocytic proteoglycans, and several of his human chondrocyte cell models remain in use in laboratories on four continents. His interests subsequently broadened to include the role of aberrant biomechanical loading in lower extremity osteoarthritis. He leads a large multidisciplinary group that studies osteoarthritis from a broad perspective, including joint tissue biology, neurobiology of musculoskeletal pain, and mechanical mediators of osteoarthritis progression, all with the focus on identifying novel therapeutic strategies.
Dr. Block served as Editor-in-Chief of Osteoarthritis and Cartilage from 2016 until 2022 and remains a member of the Editorial Board. In addition, he is a member of the Editorial Boards of the Journal of Clinical Rheumatology, Osteoarthritis and Cartilage Open, and Journal of Orthopaedic
Research. He has served on the Boards of Directors of the American College of Rheumatology, the Osteoarthritis Research Society International, and as Vice President of the U.S. Bone & Joint Initiative. He has served on, and chaired, numerous grant review panels for the NIH, Arthritis Foundation, Defense Department, and several overseas granting authorities. -
-
David Felson, MD
Dr. David Felson is Evans Distinguished Professor of Medicine and Epidemiology at Boston University. For his arthritis research, he has received both the OARSI Clinical Research Award and an OARSI Lifetime Achievement Award and was the first ever recipient of the American College of Rheumatology clinical research award. He has won the Howley Prize from the Arthritis Foundation twice, most recently in 2020.
His major research contributions have been in osteoarthritis and rheumatoid arthritis. In osteoarthritis, he founded the Framingham Heart Study Osteoarthritis Study and cofounded the Multicenter Osteoarthritis (MOST Study). He pioneered studies showing that obesity caused knee osteoarthritis and that weight loss prevented it. He also introduced MRI into large scale studies and his group showed that synovitis and bone marrow lesions, injury lesions to bone deep to cartilage, were major sources of pain. As a consequence, these structures may become targets of treatment. He has led placebo controlled trials in OA, participated in OA treatment guidelines committees and currently leads the Arthritis Foundation’s OA Clinical Trial Network.
In rheumatoid arthritis, Dr. Felson developed the first core set of outcomes, then led the first joint American College and European League committee to define outcomes in RA trials The recommended outcome, the ACR20, has been adopted by all regulatory agencies and is the major criterion used to approve drugs in RA.
In addition, Dr. Felson has trained many of the leading clinical researchers in rheumatology both in the US and around the world and has seen patients on an active basis for over 30 years.
-
-
C. Kent Kwoh, MD, MACR
C. Kent Kwoh is the Charles A.L. and Suzanne M. Stephens Chair of Rheumatology, Professor of Medicine and Medical Imaging, Chief of the Division of Rheumatology and Director of the University of Arizona Arthritis Center at the University of Arizona College of Medicine-Tucson.
A recipient of NIH funding since 1989, he was one of the original site PI’s for the Osteoarthritis Initiative (OAI). Dr. Kwoh and his collaborators have had a longstanding interest in the epidemiology of a broad spectrum of rheumatic and musculoskeletal diseases, with a particular focus on the epidemiology of and outcome assessment in osteoarthritis, promoting equity in the management of rheumatic and musculoskeletal diseases, and the identification of new targets for the prevention and management of knee OA. His major research contributions include the earlier detection of OA onset and/or progression using MRI imaging biomarkers, the characterization of knee pain location and patterns, the identification of imaging biomarkers of knee pain, and the identification of modifiable determinants to reduce/eliminate disparities in the utilization of joint replacement and other treatment options for osteoarthritis.
Dr. Kwoh has served on the Board of Directors of the American College of Rheumatology and the Rheumatology Research Foundation and on numerous NIH, VA and foundation review panels in the US and overseas.
-
-
Dr. Nancy E. Lane
Dr. Nancy E. Lane is a Distinguished Professor of Medicine and Rheumatology at U.C. Davis Health and Adjunct Clinical Professor of Clinical Immunology and Rheumatology at Stanford Medical Center.
Dr. Lane is a translational scientist who has worked in the field of musculoskeletal diseases of aging for over 40 years and she is an international expert on the treatment of osteoarthritis and has published over 400 peer-reviewed papers.
Dr. Lane is also president-elect of the Osteoarthritis and Cartilage Research Society International (OARSI).
The members or their institutions of our Medical Advisory Board are compensated for the time they spend working with Apos® to better our products and services.